Last reviewed · How we verify

Fosfomycin and imipenem — Competitive Intelligence Brief

Fosfomycin and imipenem (Fosfomycin and imipenem) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic combination. Area: Infectious Disease.

marketed Beta-lactam antibiotic combination Bacterial cell wall synthesis (MurA enzyme and penicillin-binding proteins) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Fosfomycin and imipenem (Fosfomycin and imipenem) — Juan A. Arnaiz. Fosfomycin and imipenem together provide dual antibiotic action by inhibiting bacterial cell wall synthesis through different mechanisms to treat serious infections.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Fosfomycin and imipenem TARGET Fosfomycin and imipenem Juan A. Arnaiz marketed Beta-lactam antibiotic combination Bacterial cell wall synthesis (MurA enzyme and penicillin-binding proteins)
Ilaprazole + Amoxicillin Ilaprazole + Amoxicillin Il-Yang Pharm. Co., Ltd. marketed Proton pump inhibitor + Beta-lactam antibiotic combination H+/K+-ATPase (ilaprazole); Bacterial cell wall peptidoglycan (amoxicillin)
Vonoprazan+amoxicillin 7 days Vonoprazan+amoxicillin 7 days Xijing Hospital of Digestive Diseases marketed Potassium-competitive acid blocker + beta-lactam antibiotic combination H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)
Rabeprazole, Amoxicillin Rabeprazole, Amoxicillin Mackay Memorial Hospital marketed Proton pump inhibitor + Beta-lactam antibiotic combination H+/K+-ATPase (rabeprazole); Bacterial penicillin-binding proteins (amoxicillin)
Ceftolozane-tazobactam + Meropenem Ceftolozane-tazobactam + Meropenem National University of Singapore marketed Beta-lactam antibiotic combination Bacterial penicillin-binding proteins (PBPs); beta-lactamase inhibition
ceftriaxone/oxacillin ceftriaxone/oxacillin UPECLIN HC FM Botucatu Unesp marketed Beta-lactam antibiotic combination Penicillin-binding proteins (PBPs)
Azithromycin and amoxicillin Azithromycin and amoxicillin University of Alabama at Birmingham marketed Macrolide and beta-lactam antibiotic combination Bacterial 50S ribosomal subunit (azithromycin); bacterial cell wall peptidoglycan (amoxicillin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic combination class)

  1. Juan A. Arnaiz · 1 drug in this class
  2. National University of Singapore · 1 drug in this class
  3. Population Health Research Institute · 1 drug in this class
  4. Radboud University Medical Center · 1 drug in this class
  5. UPECLIN HC FM Botucatu Unesp · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fosfomycin and imipenem — Competitive Intelligence Brief. https://druglandscape.com/ci/fosfomycin-and-imipenem. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: